761423-87-4 | Ipragliflozin

Packsize	Purity	Availability	Price	Discounted Price
10mg	97%	in stock	$42.00	$29.00
250mg	97%	in stock	$56.00	$39.00
1g	97%	in stock	$131.00	$92.00
5g	97%	in stock	$473.00	$331.00
10g	97%	in stock	$783.00	$548.00
25g	97%	in stock	$1,536.00	$1,075.00

Description

• Catalog Number: AI56075
• Chemical Name: Ipragliflozin
• CAS Number: 761423-87-4
• Molecular Formula: C21H21FO5S
• Molecular Weight: 404.4518
• MDL Number: MFCD19443744
• SMILES: OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2cc3c(s2)cccc3)F)[C@@H]([C@H]([C@@H]1O)O)O

Computed Properties

• Complexity: 525
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 4
• XLogP3: 2.5

Literature

• Pharmacological aspects of the safety of gliflozins.

  Pharmacological research 20170401

• Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.

  Journal of diabetes investigation 20160501

• Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

  Clinical pharmacokinetics 20150701

• No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

  Diabetes, obesity & metabolism 20121001

• Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

  Clinical therapeutics 20120801

• Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

  Bioorganic & medicinal chemistry 20120515

• Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

  Naunyn-Schmiedeberg's archives of pharmacology 20120401

• Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

  Journal of pharmacological sciences 20120101

• Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

  Diabetes technology & therapeutics 20111201

• Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

  Clinical drug investigation 20111201